Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS Article Swipe

PDF

Alessandra Spanu , Hélène E. Aschmann , Jürg Kesselring , Milo A. Puhan ·

YOU? · · 2020 · Open Access · · DOI: https://doi.org/10.1016/j.msard.2020.102464

Related Topics

Randomized Controlled Trial

Daily Dose Of Sunshine

Concepts

Fingolimod Medicine Placebo Multiple sclerosis Expanded Disability Status Scale Adverse effect Randomized controlled trial Dose Clinical trial Internal medicine Alternative medicine Psychiatry Pathology

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.1016/j.msard.2020.102464
PDF: http://www.msard-journal.com/article/S2211034820305393/pdf
OA Status: hybrid
Cited By: 3
References: 27
Related Works: 10
OpenAlex ID: https://openalex.org/W3080235847

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W3080235847

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1016/j.msard.2020.102464

Digital Object Identifier
Title: Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2020

Year of publication
Publication date: 2020-08-23

Full publication date if available
Authors: Alessandra Spanu, Hélène E. Aschmann, Jürg Kesselring, Milo A. Puhan

List of authors in order
Landing page: https://doi.org/10.1016/j.msard.2020.102464

Publisher landing page
PDF URL: https://www.msard-journal.com/article/S2211034820305393/pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: hybrid

Open access status per OpenAlex
OA URL: https://www.msard-journal.com/article/S2211034820305393/pdf

Direct OA link when available
Concepts: Fingolimod, Medicine, Placebo, Multiple sclerosis, Expanded Disability Status Scale, Adverse effect, Randomized controlled trial, Dose, Clinical trial, Internal medicine, Alternative medicine, Psychiatry, Pathology

Top concepts (fields/topics) attached by OpenAlex
Cited by: 3

Total citation count in OpenAlex
Citations by year (recent): 2022: 2, 2021: 1

Per-year citation counts (last 5 years)
References (count): 27

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W3080235847
doi	https://doi.org/10.1016/j.msard.2020.102464
ids.doi	https://doi.org/10.1016/j.msard.2020.102464
ids.mag	3080235847
ids.pmid	https://pubmed.ncbi.nlm.nih.gov/32889373
ids.openalex	https://openalex.org/W3080235847
fwci	0.52871508
mesh[0].qualifier_ui	Q000627
mesh[0].descriptor_ui	D000068876
mesh[0].is_major_topic	False
mesh[0].qualifier_name	therapeutic use
mesh[0].descriptor_name	Fingolimod Hydrochloride
mesh[1].qualifier_ui
mesh[1].descriptor_ui	D005610
mesh[1].is_major_topic	False
mesh[1].qualifier_name
mesh[1].descriptor_name	Freedom
mesh[2].qualifier_ui
mesh[2].descriptor_ui	D006801
mesh[2].is_major_topic	False
mesh[2].qualifier_name
mesh[2].descriptor_name	Humans
mesh[3].qualifier_ui	Q000009
mesh[3].descriptor_ui	D007166
mesh[3].is_major_topic	False
mesh[3].qualifier_name	adverse effects
mesh[3].descriptor_name	Immunosuppressive Agents
mesh[4].qualifier_ui	Q000188
mesh[4].descriptor_ui	D009103
mesh[4].is_major_topic	True
mesh[4].qualifier_name	drug therapy
mesh[4].descriptor_name	Multiple Sclerosis
mesh[5].qualifier_ui	Q000188
mesh[5].descriptor_ui	D020529
mesh[5].is_major_topic	True
mesh[5].qualifier_name	drug therapy
mesh[5].descriptor_name	Multiple Sclerosis, Relapsing-Remitting
mesh[6].qualifier_ui	Q000627
mesh[6].descriptor_ui	D000068876
mesh[6].is_major_topic	False
mesh[6].qualifier_name	therapeutic use
mesh[6].descriptor_name	Fingolimod Hydrochloride
mesh[7].qualifier_ui
mesh[7].descriptor_ui	D005610
mesh[7].is_major_topic	False
mesh[7].qualifier_name
mesh[7].descriptor_name	Freedom
mesh[8].qualifier_ui
mesh[8].descriptor_ui	D006801
mesh[8].is_major_topic	False
mesh[8].qualifier_name
mesh[8].descriptor_name	Humans
mesh[9].qualifier_ui	Q000009
mesh[9].descriptor_ui	D007166
mesh[9].is_major_topic	False
mesh[9].qualifier_name	adverse effects
mesh[9].descriptor_name	Immunosuppressive Agents
mesh[10].qualifier_ui	Q000188
mesh[10].descriptor_ui	D009103
mesh[10].is_major_topic	True
mesh[10].qualifier_name	drug therapy
mesh[10].descriptor_name	Multiple Sclerosis
mesh[11].qualifier_ui	Q000188
mesh[11].descriptor_ui	D020529
mesh[11].is_major_topic	True
mesh[11].qualifier_name	drug therapy
mesh[11].descriptor_name	Multiple Sclerosis, Relapsing-Remitting
type	article
title	Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS
biblio.issue
biblio.volume	46
biblio.last_page	102464
biblio.first_page	102464
topics[0].id	https://openalex.org/T10137
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9977999925613403
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2734
topics[0].subfield.display_name	Pathology and Forensic Medicine
topics[0].display_name	Multiple Sclerosis Research Studies
topics[1].id	https://openalex.org/T11308
topics[1].field.id	https://openalex.org/fields/13
topics[1].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[1].score	0.9794999957084656
topics[1].domain.id	https://openalex.org/domains/1
topics[1].domain.display_name	Life Sciences
topics[1].subfield.id	https://openalex.org/subfields/1312
topics[1].subfield.display_name	Molecular Biology
topics[1].display_name	Sphingolipid Metabolism and Signaling
topics[2].id	https://openalex.org/T11616
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9233999848365784
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2720
topics[2].subfield.display_name	Hematology
topics[2].display_name	Autoimmune and Inflammatory Disorders Research
is_xpac	False
apc_list.value	3020
apc_list.currency	USD
apc_list.value_usd	3020
apc_paid.value	3020
apc_paid.currency	USD
apc_paid.value_usd	3020
concepts[0].id	https://openalex.org/C2776036978
concepts[0].level	3
concepts[0].score	0.981170117855072
concepts[0].wikidata	https://www.wikidata.org/wiki/Q425137
concepts[0].display_name	Fingolimod
concepts[1].id	https://openalex.org/C71924100
concepts[1].level	0
concepts[1].score	0.8995686173439026
concepts[1].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[1].display_name	Medicine
concepts[2].id	https://openalex.org/C27081682
concepts[2].level	3
concepts[2].score	0.7293221354484558
concepts[2].wikidata	https://www.wikidata.org/wiki/Q269829
concepts[2].display_name	Placebo
concepts[3].id	https://openalex.org/C2780640218
concepts[3].level	2
concepts[3].score	0.5910440683364868
concepts[3].wikidata	https://www.wikidata.org/wiki/Q8277
concepts[3].display_name	Multiple sclerosis
concepts[4].id	https://openalex.org/C2780892749
concepts[4].level	3
concepts[4].score	0.5906034708023071
concepts[4].wikidata	https://www.wikidata.org/wiki/Q929518
concepts[4].display_name	Expanded Disability Status Scale
concepts[5].id	https://openalex.org/C197934379
concepts[5].level	2
concepts[5].score	0.5447782278060913
concepts[5].wikidata	https://www.wikidata.org/wiki/Q2047938
concepts[5].display_name	Adverse effect
concepts[6].id	https://openalex.org/C168563851
concepts[6].level	2
concepts[6].score	0.49078354239463806
concepts[6].wikidata	https://www.wikidata.org/wiki/Q1436668
concepts[6].display_name	Randomized controlled trial
concepts[7].id	https://openalex.org/C162156334
concepts[7].level	2
concepts[7].score	0.45147931575775146
concepts[7].wikidata	https://www.wikidata.org/wiki/Q473420
concepts[7].display_name	Dose
concepts[8].id	https://openalex.org/C535046627
concepts[8].level	2
concepts[8].score	0.4352216124534607
concepts[8].wikidata	https://www.wikidata.org/wiki/Q30612
concepts[8].display_name	Clinical trial
concepts[9].id	https://openalex.org/C126322002
concepts[9].level	1
concepts[9].score	0.35087868571281433
concepts[9].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[9].display_name	Internal medicine
concepts[10].id	https://openalex.org/C204787440
concepts[10].level	2
concepts[10].score	0.18097549676895142
concepts[10].wikidata	https://www.wikidata.org/wiki/Q188504
concepts[10].display_name	Alternative medicine
concepts[11].id	https://openalex.org/C118552586
concepts[11].level	1
concepts[11].score	0.10639992356300354
concepts[11].wikidata	https://www.wikidata.org/wiki/Q7867
concepts[11].display_name	Psychiatry
concepts[12].id	https://openalex.org/C142724271
concepts[12].level	1
concepts[12].score	0.0
concepts[12].wikidata	https://www.wikidata.org/wiki/Q7208
concepts[12].display_name	Pathology
keywords[0].id	https://openalex.org/keywords/fingolimod
keywords[0].score	0.981170117855072
keywords[0].display_name	Fingolimod
keywords[1].id	https://openalex.org/keywords/medicine
keywords[1].score	0.8995686173439026
keywords[1].display_name	Medicine
keywords[2].id	https://openalex.org/keywords/placebo
keywords[2].score	0.7293221354484558
keywords[2].display_name	Placebo
keywords[3].id	https://openalex.org/keywords/multiple-sclerosis
keywords[3].score	0.5910440683364868
keywords[3].display_name	Multiple sclerosis
keywords[4].id	https://openalex.org/keywords/expanded-disability-status-scale
keywords[4].score	0.5906034708023071
keywords[4].display_name	Expanded Disability Status Scale
keywords[5].id	https://openalex.org/keywords/adverse-effect
keywords[5].score	0.5447782278060913
keywords[5].display_name	Adverse effect
keywords[6].id	https://openalex.org/keywords/randomized-controlled-trial
keywords[6].score	0.49078354239463806
keywords[6].display_name	Randomized controlled trial
keywords[7].id	https://openalex.org/keywords/dose
keywords[7].score	0.45147931575775146
keywords[7].display_name	Dose
keywords[8].id	https://openalex.org/keywords/clinical-trial
keywords[8].score	0.4352216124534607
keywords[8].display_name	Clinical trial
keywords[9].id	https://openalex.org/keywords/internal-medicine
keywords[9].score	0.35087868571281433
keywords[9].display_name	Internal medicine
keywords[10].id	https://openalex.org/keywords/alternative-medicine
keywords[10].score	0.18097549676895142
keywords[10].display_name	Alternative medicine
keywords[11].id	https://openalex.org/keywords/psychiatry
keywords[11].score	0.10639992356300354
keywords[11].display_name	Psychiatry
language	en
locations[0].id	doi:10.1016/j.msard.2020.102464
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S2764622253
locations[0].source.issn	2211-0348, 2211-0356
locations[0].source.type	journal
locations[0].source.is_oa	False
locations[0].source.issn_l	2211-0348
locations[0].source.is_core	True
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Multiple Sclerosis and Related Disorders
locations[0].source.host_organization	https://openalex.org/P4310320990
locations[0].source.host_organization_name	Elsevier BV
locations[0].source.host_organization_lineage	https://openalex.org/P4310320990
locations[0].source.host_organization_lineage_names	Elsevier BV
locations[0].license	cc-by
locations[0].pdf_url	http://www.msard-journal.com/article/S2211034820305393/pdf
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Multiple Sclerosis and Related Disorders
locations[0].landing_page_url	https://doi.org/10.1016/j.msard.2020.102464
locations[1].id	pmid:32889373
locations[1].is_oa	False
locations[1].source.id	https://openalex.org/S4306525036
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	PubMed
locations[1].source.host_organization	https://openalex.org/I1299303238
locations[1].source.host_organization_name	National Institutes of Health
locations[1].source.host_organization_lineage	https://openalex.org/I1299303238
locations[1].license
locations[1].pdf_url
locations[1].version	publishedVersion
locations[1].raw_type
locations[1].license_id
locations[1].is_accepted	True
locations[1].is_published	True
locations[1].raw_source_name	Multiple sclerosis and related disorders
locations[1].landing_page_url	https://pubmed.ncbi.nlm.nih.gov/32889373
locations[2].id	pmh:oai:www.zora.uzh.ch:191088
locations[2].is_oa	True
locations[2].source.id	https://openalex.org/S4306401281
locations[2].source.issn
locations[2].source.type	repository
locations[2].source.is_oa	False
locations[2].source.issn_l
locations[2].source.is_core	False
locations[2].source.is_in_doaj	False
locations[2].source.display_name	Zurich Open Repository and Archive (University of Zurich)
locations[2].source.host_organization	https://openalex.org/I202697423
locations[2].source.host_organization_name	University of Zurich
locations[2].source.host_organization_lineage	https://openalex.org/I202697423
locations[2].license	cc-by
locations[2].pdf_url
locations[2].version	publishedVersion
locations[2].raw_type	info:eu-repo/semantics/publishedVersion
locations[2].license_id	https://openalex.org/licenses/cc-by
locations[2].is_accepted	True
locations[2].is_published	True
locations[2].raw_source_name	Spanu, Alessandra; Aschmann, Hélène E; Kesselring, Jürg; Puhan, Milo A (2020). Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS. Multiple Sclerosis and Related Disorders, 46:102464.
locations[2].landing_page_url
locations[3].id	doi:10.5167/uzh-191088
locations[3].is_oa	True
locations[3].source.id	https://openalex.org/S7407051291
locations[3].source.type	repository
locations[3].source.is_oa	False
locations[3].source.issn_l
locations[3].source.is_core	False
locations[3].source.is_in_doaj	False
locations[3].source.display_name	Universität Zürich, ZORA
locations[3].source.host_organization
locations[3].source.host_organization_name
locations[3].license
locations[3].pdf_url
locations[3].version
locations[3].raw_type	article-journal
locations[3].license_id
locations[3].is_accepted	False
locations[3].is_published
locations[3].raw_source_name
locations[3].landing_page_url	https://doi.org/10.5167/uzh-191088
indexed_in	crossref, datacite, pubmed
authorships[0].author.id	https://openalex.org/A5084418390
authorships[0].author.orcid	https://orcid.org/0000-0001-7790-6407
authorships[0].author.display_name	Alessandra Spanu
authorships[0].countries	CH
authorships[0].affiliations[0].institution_ids	https://openalex.org/I202697423
authorships[0].affiliations[0].raw_affiliation_string	Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
authorships[0].institutions[0].id	https://openalex.org/I202697423
authorships[0].institutions[0].ror	https://ror.org/02crff812
authorships[0].institutions[0].type	education
authorships[0].institutions[0].lineage	https://openalex.org/I202697423
authorships[0].institutions[0].country_code	CH
authorships[0].institutions[0].display_name	University of Zurich
authorships[0].author_position	first
authorships[0].raw_author_name	Alessandra Spanu
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
authorships[1].author.id	https://openalex.org/A5077967167
authorships[1].author.orcid	https://orcid.org/0000-0003-1234-4321
authorships[1].author.display_name	Hélène E. Aschmann
authorships[1].countries	CH
authorships[1].affiliations[0].institution_ids	https://openalex.org/I202697423
authorships[1].affiliations[0].raw_affiliation_string	Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
authorships[1].institutions[0].id	https://openalex.org/I202697423
authorships[1].institutions[0].ror	https://ror.org/02crff812
authorships[1].institutions[0].type	education
authorships[1].institutions[0].lineage	https://openalex.org/I202697423
authorships[1].institutions[0].country_code	CH
authorships[1].institutions[0].display_name	University of Zurich
authorships[1].author_position	middle
authorships[1].raw_author_name	Hélène E. Aschmann
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
authorships[2].author.id	https://openalex.org/A5041492328
authorships[2].author.orcid	https://orcid.org/0000-0002-8645-7364
authorships[2].author.display_name	Jürg Kesselring
authorships[2].countries	CH
authorships[2].affiliations[0].institution_ids	https://openalex.org/I4210164137
authorships[2].affiliations[0].raw_affiliation_string	RehaKliniken Valens, Zurich, Switzerland
authorships[2].institutions[0].id	https://openalex.org/I4210164137
authorships[2].institutions[0].ror	https://ror.org/05jrq1t13
authorships[2].institutions[0].type	healthcare
authorships[2].institutions[0].lineage	https://openalex.org/I4210164137
authorships[2].institutions[0].country_code	CH
authorships[2].institutions[0].display_name	Valens Clinics
authorships[2].author_position	middle
authorships[2].raw_author_name	Jürg Kesselring
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	RehaKliniken Valens, Zurich, Switzerland
authorships[3].author.id	https://openalex.org/A5083315765
authorships[3].author.orcid	https://orcid.org/0000-0003-4721-1879
authorships[3].author.display_name	Milo A. Puhan
authorships[3].countries	CH
authorships[3].affiliations[0].institution_ids	https://openalex.org/I202697423
authorships[3].affiliations[0].raw_affiliation_string	Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
authorships[3].institutions[0].id	https://openalex.org/I202697423
authorships[3].institutions[0].ror	https://ror.org/02crff812
authorships[3].institutions[0].type	education
authorships[3].institutions[0].lineage	https://openalex.org/I202697423
authorships[3].institutions[0].country_code	CH
authorships[3].institutions[0].display_name	University of Zurich
authorships[3].author_position	last
authorships[3].raw_author_name	Milo A. Puhan
authorships[3].is_corresponding	True
authorships[3].raw_affiliation_strings	Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	http://www.msard-journal.com/article/S2211034820305393/pdf
open_access.oa_status	hybrid
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS
has_fulltext	True
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10137
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9977999925613403
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2734
primary_topic.subfield.display_name	Pathology and Forensic Medicine
primary_topic.display_name	Multiple Sclerosis Research Studies
related_works	https://openalex.org/W2775228109, https://openalex.org/W2391832248, https://openalex.org/W2910208719, https://openalex.org/W3149632530, https://openalex.org/W2904853615, https://openalex.org/W3025003623, https://openalex.org/W2904720124, https://openalex.org/W2316253993, https://openalex.org/W2079246512, https://openalex.org/W2161929451
cited_by_count	3
counts_by_year[0].year	2022
counts_by_year[0].cited_by_count	2
counts_by_year[1].year	2021
counts_by_year[1].cited_by_count	1
locations_count	4
best_oa_location.id	doi:10.1016/j.msard.2020.102464
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S2764622253
best_oa_location.source.issn	2211-0348, 2211-0356
best_oa_location.source.type	journal
best_oa_location.source.is_oa	False
best_oa_location.source.issn_l	2211-0348
best_oa_location.source.is_core	True
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Multiple Sclerosis and Related Disorders
best_oa_location.source.host_organization	https://openalex.org/P4310320990
best_oa_location.source.host_organization_name	Elsevier BV
best_oa_location.source.host_organization_lineage	https://openalex.org/P4310320990
best_oa_location.source.host_organization_lineage_names	Elsevier BV
best_oa_location.license	cc-by
best_oa_location.pdf_url	http://www.msard-journal.com/article/S2211034820305393/pdf
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Multiple Sclerosis and Related Disorders
best_oa_location.landing_page_url	https://doi.org/10.1016/j.msard.2020.102464
primary_location.id	doi:10.1016/j.msard.2020.102464
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S2764622253
primary_location.source.issn	2211-0348, 2211-0356
primary_location.source.type	journal
primary_location.source.is_oa	False
primary_location.source.issn_l	2211-0348
primary_location.source.is_core	True
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Multiple Sclerosis and Related Disorders
primary_location.source.host_organization	https://openalex.org/P4310320990
primary_location.source.host_organization_name	Elsevier BV
primary_location.source.host_organization_lineage	https://openalex.org/P4310320990
primary_location.source.host_organization_lineage_names	Elsevier BV
primary_location.license	cc-by
primary_location.pdf_url	http://www.msard-journal.com/article/S2211034820305393/pdf
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Multiple Sclerosis and Related Disorders
primary_location.landing_page_url	https://doi.org/10.1016/j.msard.2020.102464
publication_date	2020-08-23
publication_year	2020
referenced_works	https://openalex.org/W2529707400, https://openalex.org/W2564334902, https://openalex.org/W6775094652, https://openalex.org/W2996275081, https://openalex.org/W2095263941, https://openalex.org/W1985687068, https://openalex.org/W2551593802, https://openalex.org/W2732925669, https://openalex.org/W2104948944, https://openalex.org/W2112165124, https://openalex.org/W1929363088, https://openalex.org/W2138994078, https://openalex.org/W1977733462, https://openalex.org/W2036605937, https://openalex.org/W2136658595, https://openalex.org/W1964905091, https://openalex.org/W2156522198, https://openalex.org/W2902104113, https://openalex.org/W2806064879, https://openalex.org/W1929654807, https://openalex.org/W2098891370, https://openalex.org/W2790403673, https://openalex.org/W2414286345, https://openalex.org/W4377086257, https://openalex.org/W1224047275, https://openalex.org/W4256713203, https://openalex.org/W3011008730
referenced_works_count	27
abstract_inverted_index
cited_by_percentile_year.max	96
cited_by_percentile_year.min	89
corresponding_author_ids	https://openalex.org/A5083315765
countries_distinct_count	1
institutions_distinct_count	4
corresponding_institution_ids	https://openalex.org/I202697423
sustainable_development_goals[0].id	https://metadata.un.org/sdg/16
sustainable_development_goals[0].score	0.7099999785423279
sustainable_development_goals[0].display_name	Peace, Justice and strong institutions
citation_normalized_percentile.value	0.63521721
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False